BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31383962)

  • 1. Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Lanjewar S; Patil P; Fineberg S
    Mod Pathol; 2020 Jan; 33(1):91-98. PubMed ID: 31383962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
    Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
    Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
    Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
    Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
    Sahoo S; Lester SC
    Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
    Thomas JSJ; Provenzano E; Hiller L; Dunn J; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham J; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Caldas C; Bartlett JM; Cameron DA; Hayward RL; Earl HM
    Mod Pathol; 2017 Aug; 30(8):1069-1077. PubMed ID: 28548129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
    See SHC; Siziopikou KP
    Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
    Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Specimen Processing and Reporting With an Emphasis on Margin Evaluation: A College of American Pathologists Survey of 866 Laboratories.
    Guidi AJ; Tworek JA; Mais DD; Souers RJ; Blond BJ; Brown RW
    Arch Pathol Lab Med; 2018 Apr; 142(4):496-506. PubMed ID: 29328775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
    Bossuyt V; Spring L
    Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Bossuyt V; Provenzano E; Symmans WF; Webster F; Allison KH; Dang C; Gobbi H; Kulka J; Lakhani SR; Moriya T; Quinn CM; Sapino A; Schnitt S; Sibbering DM; Slodkowska E; Yang W; Tan PH; Ellis I
    Histopathology; 2024 Jun; 84(7):1111-1129. PubMed ID: 38443320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
    Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
    Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions.
    Nakhleh RE; Jones B; Zarbo RJ
    Arch Pathol Lab Med; 1997 Jan; 121(1):11-8. PubMed ID: 9111087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy.
    Pinder SE; Provenzano E; Earl H; Ellis IO
    Histopathology; 2007 Mar; 50(4):409-17. PubMed ID: 17448015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
    Bossuyt V
    Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.